Cancer vaccines catch ride on UNC-created nanoparticle; Circassia grabs license to microneedle system;

> Research at the University of North Carolina, Chapel Hill found that new nanoparticles could potentially deliver the chemo drug oxaliplatin to tough-to-treat tumors of the colon and pancreas. Item

> A new nanoparticle might offer an efficient and effective delivery vehicle for cancer vaccines. Abstract

> Branching off from its contract-manufacturing roots, SCM Pharma said it is ready to begin its formulation development business with facilities the U.K.-based firm acquired from the University of Sunderland. Release

> NanoPass Technologies has struck a licensing deal with the U.K.'s Circassia that gives Circassia access to NanoPass's microneedle intradermal delivery system for allergy medicines and other therapies. Report

> Allergy Therapeutics has shelled out £600,000 to expand its rights to distribute the Anapen epinephrine pen auto-injector in the U.K. and Ireland. Lincoln Medical's Anapen is used to treat anaphylactic shock. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.